Many interesting studies on urological infection have been published in the past year including nonantibiotic therapy for acute cystitis, the utility of the Acute Cystitis Symptom Score, specific identification of health-care-associated urinary tract infection and a multidisciplinary approach to prostatitis.
Key advances
A phase III trial showed that herbal therapy was noninferior to antibiotics for treatment of acute cystitis1.
The applicability of the Acute Cystitis Symptom Score for diagnosing acute cystitis and measuring patient-reported outcome measures was assessed in two studies2,3.
A mathematical model was used to improve empirical antibiotic therapy by specific identification of health-care-associated urinary tract infection, which also could help to reduce antimicrobial resistance4.
An expert panel recommended a multidisciplinary approach to prostatitis5.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wagenlehner, F. M. et al. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol. Int. 101, 327–336 (2018).
Alidjanov, J. F. et al. Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women. World J. Urol. https://doi.org/10.1007/s00345-019-02761-3 (2019).
Alidjanov, J. F. et al. Additional assessment of acute cystitis symptom score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II. World J. Urol. https://doi.org/10.1007/s00345-019-02948-8 (2019).
Tandogdu, Z. et al. Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study. World J. Urol. https://doi.org/10.1007/s00345-019-02963-9 (2019).
Magri, V. et al. Multidisciplinary approach to prostatitis. Arch. Ital. Urol. Androl. 90, 227–248 (2018).
European Medicines Agency. Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, Rev. 3. EMA https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf (2018).
U.S. Department of Health and Human Services, Food and Drug Administration & Center for Drug Evaluation and Research (CDER). Uncomplicated urinary tract infections: developing drugs for treatment guidance for industry. FDA https://www.fda.gov/media/129531/download (2019).
Wagenlehner, F. et al. The global prevalence of infections in urology study: a long-term, worldwide surveillance study on urological infections. Pathogens 5, E10 (2016).
Krieger, J. N., Nyberg, L. J. & Nickel, J. C. NIH consensus definition and classification of prostatitis. JAMA 282, 236–237 (1999).
Magri, V. et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp. Ther. Med. 9, 658–666 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.G.N declares personal fees from Adamed, Allecra, Apogepha, Aristo, Bionorica, Biomerieux, Enteris, GlaxoSmithKline (GSK), Gruenenthal Mexico, Helperby, Marpinion, MerLion, Medice, Merck Sharp & Dohme (MSD), OM Pharma/Vifor, Paratek, Roche, Saxonia and Zambon and non-financial support from Mission Pharmacal, outside the submitted work. F.M.E.W. declares other fees from Achaogen, Bionorica, OM Pharma/Vifor Pharma and Shionogi, and personal fees from AstraZeneca, Bionorica, Enteris BioPharma, GSK, Janssen, LeoPharma, MerLion, MSD, Pfizer, RosenPharma and VenatoRx, and other from Helperby Therapeutics and Deutsches Zentrum für Infektionsforschung (DZIF; Giessen-Marburg-Langen site), outside the submitted work.
Additional information
Related links
ACSS: www.acss.world
Rights and permissions
About this article
Cite this article
Naber, K.G., Wagenlehner, F.M.E. Recent research in urological infections. Nat Rev Urol 17, 65–66 (2020). https://doi.org/10.1038/s41585-019-0264-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0264-5
